TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
16.26
-0.02 (-0.12%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close16.28
Open16.34
Bid0.00 x 0
Ask0.00 x 0
Day's Range16.10 - 16.44
52 Week Range16.03 - 31.29
Volume6,095,095
Avg. Volume1,860,214
Market Cap26.215B
Beta (3Y Monthly)0.42
PE Ratio (TTM)20.04
EPS (TTM)0.81
Earnings DateN/A
Forward Dividend & Yield0.79 (4.71%)
Ex-Dividend Date2018-09-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • $59bln: What it costs to become a drugs player
    Reuters Videos7 days ago

    $59bln: What it costs to become a drugs player

    Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. Julian Satterthwaite reports.

  • What Are Tesaro’s Revenue Projections for Fiscal 2018?
    Market Realist9 hours ago

    What Are Tesaro’s Revenue Projections for Fiscal 2018?

    How Is Tesaro Positioned in December? In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million. According to the company’s third-quarter earnings conference call, Tesaro is expected to have cash and cash equivalents worth $400 million on its balance sheet at the end of fiscal 2018.

  • Takeda Downgrade Looms After Shareholders Approve Shire Deal
    Bloomberg6 days ago

    Takeda Downgrade Looms After Shareholders Approve Shire Deal

    The backing of what will be the largest-ever overseas purchase by a Japanese company paves the way for possible downgrades to the lowest tiers before junk ratings at both S&P Global Ratings and Moody’s Investors Service. What happens after that depends on how quickly Takeda can reduce its debt burden, including progress in potential non-core asset sales worth up to $10 billion, analysts at the ratings companies say. Takeda pulled off a mammoth dollar- and euro-note bond sale last month, and NLI Research Institute said investors are interested in how much the acquisition ultimately benefits the Japanese drug maker.

  • The Wall Street Journal6 days ago

    [$$] Takeda Wins Shareholder Approval for Its Shire Megadeal

    Takeda Pharmaceutical Co. shareholders voted in favor of its megadeal to buy Europe’s Shire PLC on Wednesday, crushing an opposition campaign that sought to derail the biggest overseas acquisition by a Japanese company. At least 88% of votes cast were in favor, according to Takeda, dealing a blow to a group of longtime shareholders who had lobbied to block the cash-and-stock merger, valued at about $58 billion today. The dissidents argued Takeda was overpaying for Shire and piling on too much debt to do so, though they conceded before the vote that they hadn’t won enough support to derail the deal.

  • Reuters6 days ago

    Takeda clears key hurdle as investors back $59 billion Shire deal

    Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. Takeda will be joining the ranks of the world's top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company. The company's high debt levels were a top concern for Takeda shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 percent of them voted to approve the deal as expected.

  • Takeda clears key hurdle as investors back $59 billion Shire deal
    Reuters6 days ago

    Takeda clears key hurdle as investors back $59 billion Shire deal

    Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire (SHP.L), creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. Takeda will be joining the ranks of the world's top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company. The company's high debt levels were a top concern for Takeda shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 percent of them voted to approve the deal as expected.

  • Takeda's Long Battle for $62 Billion Shire Deal Gets Victory
    Bloomberg6 days ago

    Takeda's Long Battle for $62 Billion Shire Deal Gets Victory

    Now the Frenchman has emerged victorious as 88 percent of Takeda shareholders voted in support of the acquisition, virtually ending Weber’s nine-month campaign to secure Shire, whose investors overwhelmingly backed the deal. The Takeda vote represents a clear endorsement of Weber’s vision to transform the 237-year-old company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the U.S. The scope of the combination underscores Weber’s ambitions: it’s the biggest acquisition announced globally this year and the largest overseas takeover ever by a Japanese company.

  • Reuters7 days ago

    Takeda investors back $59 billion Shire deal, but wary of debt load

    Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion (46.3 billion pounds) takeover of London-listed Shire (SHP.L), creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. Takeda will be joining the ranks of the world's top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company. The company's high debt levels were a top concern for shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 percent of them voted to approve the deal as expected.

  • Financial Times7 days ago

    [$$] Takeda wins shareholder approval for £46bn Shire acquisition

    by founding family members to derail a deal that the 237-year-old group sees as pivotal to securing its place among the world’s top 10 pharmaceutical companies. Following an extraordinary meeting in Osaka, Takeda said it had won approval from nearly 90 per cent of its shareholders to issue new shares to acquire the Irish drugmaker. “The Japanese market represents 7 per cent of the global market.

  • Financial Times7 days ago

    [$$] Takeda/haemophilia: blood test

    Drug companies do not normally put shows on Broadway. But BioMarin ’s sponsorship of Hemophilia: The Musical , made sense. Last month’s performance — involving 25 teenagers with the bleeding disorder — ...

  • Reuters21 days ago

    EU approves Takeda buying Shire, on divestment condition

    The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc (SHP.L) by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development. In a statement, the Commission said Takeda had agreed to the sale in order to ensure that the drug in Shire's product pipeline aimed at treating inflammatory bowel disease would continue its way to the market, where it is expected to compete with Entyvio, Takeda's biggest-selling drug.

  • Reuters21 days ago

    Investor advisory firms back Takeda's $62 billion deal for Shire

    Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion (48 billion pounds) takeover offer for drugmaker Shire (SHP.L), dealing a blow to a group of investors who hope to block the deal. Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support. It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.

  • Takeda Heads to Shire Vote With Backing from EU, Advisory Groups
    Bloomberg21 days ago

    Takeda Heads to Shire Vote With Backing from EU, Advisory Groups

    The European Commission signed off on the deal Tuesday after the Japanese drugmaker agreed to sell an experimental treatment for inflammatory bowel disease from Shire to satisfy antitrust concerns. Europe was the final step after the takeover gained approval by other major markets from China to the U.S. The deal also got a boost as advisory groups Glass Lewis and Institutional Shareholder Services recommended that investors back the acquisition. “We are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader,” Chief Executive Officer Christophe Weber said in a statement.

  • EU approves Takeda buying Shire, on divestment condition
    Reuters21 days ago

    EU approves Takeda buying Shire, on divestment condition

    The European Commission said on Tuesday that it approved the $62-billion takeover of London's Shire plc (SHP.L) by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development. In a statement, the Commission said Takeda had agreed to the sale in order to ensure that the drug in Shire's product pipeline aimed at treating inflammatory bowel disease would continue its way to the market, where it is expected to compete with Entyvio, Takeda's biggest-selling drug.

  • Investor advisory firms back Takeda's $62 billion deal for Shire
    Reuters21 days ago

    Investor advisory firms back Takeda's $62 billion deal for Shire

    Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion takeover offer for drugmaker Shire (SHP.L), dealing a blow to a group of investors who hope to block the deal. Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support. It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.

  • Takeda's Dissident Holders Keep Trying to Kill Shire Deal
    Bloomberg22 days ago

    Takeda's Dissident Holders Keep Trying to Kill Shire Deal

    The group has put out invitations to shareholders for emergency meetings this week after the deal is expected to be approved by Europe on Tuesday in its final major regulatory hurdle. The group, called “Thinking About Takeda’s Future” and formed after the announcement of Takeda’s takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker. Some members are part of the founding Takeda family.

  • Bloomberg22 days ago

    Takeda Moves Quickly to Sell Dollar Bonds for Shire Plc Deal

    Takeda seems more focused on deal execution than avoiding paying a few extra basis points by picking a perfect moment to sellThe company has opted to bias its Shire-related bond issuance toward euros, maybe to take advantage of lower yields in the currency. It didn’t have outstanding euro debt until it sold a six-part deal last week but it does have one outstanding dollar bond, a 2.45 percent Jan. 2022 security that’s yielding just under 4 percent Takeda’s chosen not to raise long-dated bonds. This may suggest the company is thinking about potential further issuance in the future when market conditions are better and the Shire acquisition has bedded inThe company is tapping the dollar debt market during a turbulent time for new bonds.

  • Moody's26 days ago

    Takeda Pharmaceutical Company Limited -- Moody's assigns A2 to Takeda's proposed notes; places rating under review for downgrade

    Moody's Japan K.K. has assigned A2 ratings to Takeda Pharmaceutical Company Limited's (A2 review for downgrade) proposed senior unsecured notes. These new notes are under review for downgrade as are Takeda's ...

  • Revenue Projections for Endo International for 2018
    Market Realist29 days ago

    Revenue Projections for Endo International for 2018

    On its third-quarter earnings conference call, Endo International (ENDP) raised its revenue guidance for 2018 from the previously projected range of $2.75 billion–$2.85 billion to $2.87 billion–$2.92 billion mainly due to its stronger-than-anticipated performance YTD (year-to-date).

  • Reuters29 days ago

    Takeda's Shire takeover to bring $963 million fee bonanza

    Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire (SHP.L), according to documents for the deal published on Monday. The deal will be the largest-ever overseas acquisition by a Japanese company and will lead to big payments to advisers working on both sides of the transaction. The Japanese company expects spend about $733.4 million in fees and expenses in total, while London-listed Shire's costs will range between $216.5 million and $229.5 million, the companies disclosed in the documents.

  • Reuters29 days ago

    Takeda's Shire takeover to bring $963 million fee bonanza

    Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire (SHP.L), according to documents for the deal published on Monday. The deal will be the largest-ever overseas acquisition by a Japanese company and will lead to big payments to advisers working on both sides of the transaction. The Japanese company expects spend about $733.4 million in fees and expenses in total, while London-listed Shire's costs will range between $216.5 million and $229.5 million, the companies disclosed in the documents.